Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody engineering using Escherichia coli as host

E S Ward1

  • 1Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas 75235.

Advances in Pharmacology (San Diego, Calif.)
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.

The British journal of dermatology·2021
Same author

Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux through Rabbit Rectal Membrane.

International journal of pharmaceutical compounding·2013
Same author

Quantitative study of single molecule location estimation techniques.

Optics express·2010
Same author

Predictors of blood product use in orthotopic liver transplantation using the piggyback hepatectomy technique.

Transplantation proceedings·2007
Same author

Noise suppression of point spread functions and its influence on deconvolution of three-dimensional fluorescence microscopy image sets.

Journal of microscopy·2005
Same author

In vitro anti-inflammatory effects and immunomodulation by gemifloxacin in stimulated human THP-1 monocytes.

Die Pharmazie·2004
Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from phage display.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Physiological strategies for brain delivery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from natural proteins.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

In vitro blood-brain barrier models for the study of brain shuttle peptide transport.

Advances in pharmacology (San Diego, Calif.)·2026
See all related articles

Recombinant antibody fragments like Fv, Fab, and scFv can now be routinely produced in E. coli. This technology offers a rapid, alternative route to traditional hybridoma methods for generating antigen-binding proteins.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Immunology

Background:

  • Escherichia coli (E. coli) expression systems enable routine production of functional immunoglobulin fragments.
  • Antibody fragments such as Fv, Fab, and single-chain variable fragments (scFv) can be secreted in significant yields (milligrams per liter).

Purpose of the Study:

  • To highlight the advancements in producing antibody fragments using E. coli expression systems.
  • To discuss the potential of repertoire cloning and selection for generating antibody fragments with specific antigen-binding activities.
  • To explore the future implications of this technology as an alternative to hybridoma technology.

Main Methods:

  • Utilizing E. coli expression systems for the production of Fv, Fab, and scFv fragments.
  • Employing repertoire cloning and polymerase chain reaction (PCR) to isolate diverse variable heavy (VH) and variable light (VL) domain genes.

Related Experiment Videos

  • Developing systems for random mutagenesis and selection to enhance antibody fragment affinity.

    • Main Results:

    • Successful production of secreted antibody fragments (Fv, Fab, scFv, single VH domains) in E. coli at yields of milligrams per liter.
    • Development of expression systems for antibody fragment production via repertoire cloning and selection.
    • Isolation and cloning of diverse VH and VL gene repertoires for expression and selection of desired antigen-binding specificities.

    Conclusions:

    • E. coli expression systems provide a robust platform for producing various antibody fragments.
    • Repertoire cloning coupled with selection offers a rapid method for identifying antibody fragments with specific binding properties.
    • This evolving technology has the potential to become a faster alternative to hybridoma technology for antibody discovery and development.